Product information and disease descriptionProduct description
Phase of product development
9 evidence topics · 15 sources
Regulatory status: Submission planned; NDA submission planned by the end of 2026
Launch
No evidence found.
Approval timing assumed in the company's exclusivity projection: second half of 2027
Analyst assumption of U.S. market entry in 2027 (LifeSci Capital, June 2026)
Development phase: phase 3 in moderately to severely active ulcerative colitis
NDA submission timing: company guidance from January 2026 to May 2026
Marketing authorization application to the EMA: planned for the second half of 2026, July 2025 statement
EU paediatric investigation plan for ulcerative colitis: modification accepted in March 2025
| Field | Quoted record |
|---|---|
| Decision | “EMA/PE/0000189672” |
| Decision date | “of 20 March 2025” |
| Condition | “Treatment of ulcerative colitis” |
| Indication targeted by the PIP | “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)” |
| Paediatric subset concerned | “From 2 years to less than 18 years of age” |
| Waiver | “the paediatric population from birth to less than 2 years of age;” |
| Paediatric clinical study | “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.” |
| Date of completion of the PIP | “By June 2029” |
| Deferral | “Yes” |